Wojciech Kuncman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wojciech Kuncman has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Bienkiewicz
Medical University in Lodz, Lodz, Poland
1 shared publication - Andrzej Marszałek
Department of Pathology, Poznan University Medical Sciences and Greater Poland Cancer Center, 61-701 Poznan, Poland
1 shared publication - Andrzej Roszak
Department of Radiotherapy and Oncological Gynecology, Greater Poland Cancer Center, 61-866 Poznan, Poland
1 shared publication - Anita Olejek
Department of Gynaecology, Obstetrics and Oncological Gynaecology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
1 shared publication - Anna Gryboś
Department of Gynecology and Obstetrics, Faculty of Health Sciences, Wroclaw Medical University, 50-367 Wroclaw, Poland
1 shared publication - Anna Markowska
Department of Perinatology, Poznań University of Medical Sciences, Polna 33, 60-535 Poznań, Poland
1 shared publication
Latest Publications
- Open Access
- 12 September 2019
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 28 (10) , 1359-1365
A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification
High-grade B-cell lymphomas (HGBLs) comprise a new entity in the revised 2016/2017 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. The diagnosis of HGBL encompasses histopathology and immunohistochemistry, with additional molecular examination of the BCL2/MYC or BCL6/MYC rearrangement status. The aim of the study was to summarize our experience in the histopathological and immunohistochemical diagnosis of patients with aggressive B-cell lymphomas according to the revised 2016/2017 WHO classifications. We reviewed our single-institution experience with accurate diagnoses of HGBL and diffuse large B-cell lymphoma (DLBCL) using the available histopathological and immunohistochemical tools. The timeframe was from January 1, 2017 to April 18, 2018. Out of 265 patients, 217 (81.9%) were diagnosed with DLBCL, 43 (16.2%) with HGBL/DLBCL and 5 (1.9%) with not otherwise specified HGBL (HGBL-NOS). Regarding concurrent expression of MYC and BCL2 and/or BCL6 (double expressors (DE) and triple expressors (TE)), more DE and TE cases were found in the HGBL/DLBCL group than in the DLBCL group (25.53% vs 8.47%, p < 0.001, for DE cases and 55.32% vs 6.21%, p < 0.001, for TE cases). All 48 (100.00%) of the HGBL-NOS and HGBL/DLBCL patients, and 26 (11.98%) of the DLBCL-DE/TE cases were recommended for molecular analysis. Our findings show that a comprehensive histopathological and immunohistochemical examination may identify potential HGBL cases. This study emphasizes the need to introduce a suitable molecular examination for patients with HGBL morphology and/or double/triple expression of BCL2/BCL6/MYC proteins.
- 12 September 2019
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 28 (10) , 1359-1365
Open AccessA large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification
High-grade B-cell lymphomas (HGBLs) comprise a new entity in the revised 2016/2017 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. The diagnosis of HGBL encompasses histopathology and immunohistochemistry, with additional molecular examination of the BCL2/MYC or BCL6/MYC rearrangement status. The aim of the study was to summarize our experience in the histopathological and immunohistochemical diagnosis of patients with aggressive B-cell lymphomas according to the revised 2016/2017 WHO classifications. We reviewed our single-institution experience with accurate diagnoses of HGBL and diffuse large B-cell lymphoma (DLBCL) using the available histopathological and immunohistochemical tools. The timeframe was from January 1, 2017 to April 18, 2018. Out of 265 patients, 217 (81.9%) were diagnosed with DLBCL, 43 (16.2%) with HGBL/DLBCL and 5 (1.9%) with not otherwise specified HGBL (HGBL-NOS). Regarding concurrent expression of MYC and BCL2 and/or BCL6 (double expressors (DE) and triple expressors (TE)), more DE and TE cases were found in the HGBL/DLBCL group than in the DLBCL group (25.53% vs 8.47%, p < 0.001, for DE cases and 55.32% vs 6.21%, p < 0.001, for TE cases). All 48 (100.00%) of the HGBL-NOS and HGBL/DLBCL patients, and 26 (11.98%) of the DLBCL-DE/TE cases were recommended for molecular analysis. Our findings show that a comprehensive histopathological and immunohistochemical examination may identify potential HGBL cases. This study emphasizes the need to introduce a suitable molecular examination for patients with HGBL morphology and/or double/triple expression of BCL2/BCL6/MYC proteins.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17118
Evaluation of selected molecular parameters in two types of endometrial cancer.
E17118 Background: Multiple factors linked to etiology, clinical course and prognosis in two types of endometrial cancer (endometrioid type I and non-endometrioid type II cancer) have been recognised .These include alterations in concentrations of estrogen and progesterone hormones, mutations in MMR (mismatch repair) genes, PTEN, TP53, beta-catenin, disturbed signalling pathways (e.g. PI3K/AKT). However, in several studies, including the data of Epidemiology of Endometrial Cancer Consortium, endometrial cancers and those of type II (serous carcinoma and clear-cells carcinoma) in particular proved to be more heterogenous than expected (1),(2),(3). Methods: The study manifested a multi-centre character. Using sections of paraffin-embedded preparations and immunocytochemistry with application of specific antibodies, in 115 patients with EC type I and in 31 patients with EC type II, the expression of ER ß1, ER ∂, PR and BRCA1 was estimated. Results: Expression of ER ß1 was augmented in USC (type II ), in cancers of a poor differentiation(G3), it was more pronounced in cancers of an increased clinical advancement according to FIGO. Expression of ER ∂ was detected in the endometrioid type I cancer manifesting good histological differentiation (G1or G2) and a low clinical degree of advancement according to FIGO. In over 50% cases of EC type II a mutation was detected in BRCA1, associated with a decreased expression of ER ∂. Conclusions: An augmented expression of ER ß1 in EC was linked to poor prognosis in type II EC. Higher expression of ER ∂ in type I EC of increased maturity was associated with a good prognosis. It seems that type II EC is partially connected to BRCA1 mutation.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17118
Evaluation of selected molecular parameters in two types of endometrial cancer.
E17118 Background: Multiple factors linked to etiology, clinical course and prognosis in two types of endometrial cancer (endometrioid type I and non-endometrioid type II cancer) have been recognised .These include alterations in concentrations of estrogen and progesterone hormones, mutations in MMR (mismatch repair) genes, PTEN, TP53, beta-catenin, disturbed signalling pathways (e.g. PI3K/AKT). However, in several studies, including the data of Epidemiology of Endometrial Cancer Consortium, endometrial cancers and those of type II (serous carcinoma and clear-cells carcinoma) in particular proved to be more heterogenous than expected (1),(2),(3). Methods: The study manifested a multi-centre character. Using sections of paraffin-embedded preparations and immunocytochemistry with application of specific antibodies, in 115 patients with EC type I and in 31 patients with EC type II, the expression of ER ß1, ER ∂, PR and BRCA1 was estimated. Results: Expression of ER ß1 was augmented in USC (type II ), in cancers of a poor differentiation(G3), it was more pronounced in cancers of an increased clinical advancement according to FIGO. Expression of ER ∂ was detected in the endometrioid type I cancer manifesting good histological differentiation (G1or G2) and a low clinical degree of advancement according to FIGO. In over 50% cases of EC type II a mutation was detected in BRCA1, associated with a decreased expression of ER ∂. Conclusions: An augmented expression of ER ß1 in EC was linked to poor prognosis in type II EC. Higher expression of ER ∂ in type I EC of increased maturity was associated with a good prognosis. It seems that type II EC is partially connected to BRCA1 mutation.